Patients with glioma do not have an increased risk of COVID-19 diagnosis or worse outcomes from COVID-19, according to research presented in a poster at the Society for Neuro-Oncology 27th Annual Meeting.1
The incidence of COVID-19 in this single-center study of glioma patients was lower than the incidence of COVID-19 in the general population, according to researchers.
In addition, the incidence of COVID-19 hospitalization in this study was lower than the incidence observed in an analysis of patients from the COVID-19 and Cancer Consortium Registry.
However, more than 80% of patients in the current study had their cancer treatment delayed due to COVID-19. Although none of the patients died from COVID-19-related complications, about 17% died from other causes.
This study included adults with glioma and COVID-19 seen in the department of neurology at Stanford Medicine between January 1, 2020, and June 30, 2022. The researchers also identified patients without a COVID-19 diagnosis to quantify the total number of patients seen in the clinic during that timeframe.
There were 29 cases of COVID-19 in 28 glioma patients. This translates to an incidence of 6.4% among the clinic’s glioma patients. The researchers noted that, at the time of their analysis, the US Centers for Disease Control and Prevention estimated a 26.8% incidence of COVID-19 in the general population.
The COVID-19 patients in the current study had astrocytoma (62.1%), oligodendroglioma (24.1%), mesiotemporal angiocentric glioma (6.9%), ependymoma (3.4%), or subependymal giant cell astrocytoma (3.4%). Most patients had grade 4 …